Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fimasartan + atorvastatin is a fixed-dose combination of two small molecule drugs used to treat patients with both hypertension and dyslipidemia. Fimasartan is an angiotensin II receptor antagonist (ARB) that lowers blood pressure by blocking the action of angiotensin II at the type 1 receptor, leading to vasodilation and reduced aldosterone secretion. Atorvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. The combination targets cardiovascular risk factors by addressing both elevated blood pressure and abnormal lipid profiles. This fixed-dose combination has been shown to have limited clinically significant pharmacokinetic interactions, making it suitable for co-administration in patients requiring both antihypertensive and lipid-lowering therapy[3][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fimasartan + atorvastatin.